RESEARCH DATABASE

InBody Scholar

InBody continues to work closely with academic researchers on a global scale to develop more in-depth clinical applications of body composition.
With our long history in the industry, we provide more than 6,000 research and publications.
Research title with ★ indicates InBody recommended paper.

Impact of the 8-week administration of tofogliflozin for glycemic control and body composition in Japanese patients with type 2

Endocrinology
Author
Hirose S et al.
Used Parameters : TBW, ECW, ICW, FFM, BFM, PBF, WHR

Publication Year : 2016

Country : Japan

Journal : Internal Medicine

Objective The adverse effects of selective sodium-glucose co-transporter 2 (SGLT2) inhibitors generally appear within about two or three months after treatment initiation in Japan. Therefore, we investigated the impact of tofogliflozin, a class of SGLT2 inhibitors, on glycemic control and body composition during this period in Japanese patients with type 2 diabetes mellitus. Methods This single-arm open-label study enrolled 20 patients. Patients received tofogliflozin 20 mg once daily for 8 weeks. At week 8, changes from baseline in …
Full text